Ionis Pharmaceuticals has drawn simultaneous bullish signals from three separate directions in the week before its October 28 earnings print. BMO Capital upgraded the stock this morning. Options positioning sits nearly two standard deviations below its 20-day mean on put-call ratio. Retail attention has spiked to levels rarely seen in the past 90 days.
IONS BMO Capital upgrades to Outperform, raises PT to $66 from $54, implying 49% upside from $44.27 close. Consensus target now $82.91.
Key data as of 8 Nov 2026
IONS BMO Capital upgrades to Outperform, raises PT to $66 from $54, implying 49% upside from $44.27 close. Consensus target now $82.91.
2 Analyst updates in 30 days
IONS retail attention hits 5.4 standard deviations above its own 90-day history, per Wikipedia views and ORTEX stock page data, signaling outsized interest as of October 19.
Ionis Pharmaceuticals heads into this week's earnings report with short interest at an 11-month high and the analyst community in near-uniform target-cutting mode — a combination that frames today's results as a…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IONS — free to start on ORTEX.
Sign up for free →Open IONS on ORTEX